1/9

g	aggaggct A g	cgggaaagtg	gtgcaggata	taatgccgtg	cctgcatttc
gtgaaggggg	aggagaagga	gccgtcgaag	gag A gc A gca	gcggcacgaa	gaagctgagc
gaggaggtga	agacgacgga	gcagaagagg	gaggcctgca	agtgcatagt	gcgcgccacg
aagggcatct	ccggtatcaa	aaatgaactt	gtcgccgagg	tccccaagaa	gtgcgatatt
aagaccactc	tcccgcccat	caccgccgac	ttcgactgct	ccaagatcca	aagtactatt
ttcagaggtt					. =

GGATTC

caag	aaacc A gcgg	gactatggtg	agagcgctga	tgccgtgcct	gccgttcgtg
caggggaaag	agaaagagcc	gtcaaagggg	AgcAgcagcg	gcgccaaaag	attggacggg
gagacgaaga	cggggccgca	gagggtgcac	gcttgtgagt	gcatccagac	cgccatgaag
acttattccg	acatcgacgg	gaaactcgtc	agcgaggtcc	ccaagcactg	cggcatcgtt
gacagcaagc	tcccgcccat	tgacgtcaac	atggactgca	agacagttgg	agtggttcct
cggcaacccc	aacttccagt	ctctctccgt	catggtcccg	tcacgggccc	aagtgatccc
gcccacaaag	cacggttgga	gagaccccag	attagagttc	cgccccccgc	accggaaaaa
gcc TAA				_	

Fig. 1

1 EEA S GKVVQD	IMPCLHFVKG	EEKEPSKE SS	SGTKKLSEEV	KTTEQKREAC	
51 KCIVRATKGI	SGIKNELVAE	VPKKCDIKTT	LPPITADFDC	100 SKIQSTIFRG	0
101 YY <i>GF</i> QET <u>S</u> GT	MVRALMPCLP	FVQGKEKEPS	KG SS SGAKRL	15 DGETKTGPQR	0
151 VHACECIQTA	MKTYSDIDGK	LVSEVPKHCG	IVDSKLPPID	20 VNMDCKTVGV	0
201 VPROPOLPVS	LRHGPVTGPS	DPAHKARLER	PQIRVPPPAP	243 EKA	




FIG. 3




Fig 4

5/9

Binding inhibition ELISA

	Dimer W.T	PjEDcys
Patient 1	68%	7%
Patient 2	56%	3,5%
Patient 3	62%	10%
Patient 4	62%	8%
Patient 5	62%	8%

Fig. 5






Fig. 6





		MIX	PjEDcys
\mathbf{D}		1μg/ml	lμg/ml
	Patient 1	2,9	8,5
	Patient 2	11.34	26.15
	Patient 3	3.3	3.62
	Patient 4	0.42	1.18
	Patient 5	10.44	18.86

Fig 7

8/9

% of human IgE binding inhibition

P.judaica extract	ExPj	rParj1	rParj2	rParj1 rParj2
Patient 1	94	10	80	80
Patient 2	93	53	74	74
Patient 3	90	35	37	80
Patient 4	98	59	85	86
Patient 5	100	57	29	67
Patient 6	91	29	65	69
Patient 7	94	38	58	79
Average	94,3	40,1	61,1	76,5

Fig. 8

9/9

% of human IgE binding inhibition

95%
16%
85%
14%
15%